Obesity-Linked Gut Bacteria May Worsen Graft-Versus-Host Disease

Altered gut microbiome composition in obese mice and human patients is linked with severity of disease after bone marrow transplantation, a study found.

Written byAsher Jones
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: Gut bacteria partly explain why obese mice had worse outcomes than lean individuals after bone marrow transplantation.
LAM KHUAT

The paper
L.T. Khuat et al., “Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantation,” Sci Trans Med, 12:eaay7713, 2020.

Bone marrow transplants are widely used to treat certain cancers and blood diseases, but these procedures run the risk of a serious complication called graft-versus-host disease (GVHD). This immune disorder occurs when donor T cells recognize the recipient’s body as foreign, triggering inflammatory immune responses that damage the patient’s organs and can cause death. Previous studies have shown that obesity can influence immune responses, but its effects on GVHD are poorly understood.

To interrogate the effect of obesity on bone marrow transplant outcomes, UC Davis Health immunologist William Murphy and his team used a donor-recipient mouse strain combination in which transplantation usually causes GVHD in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

April 2021

Advancing Against Metastasis

Cancer cells can spread early and lie dormant for years

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies